HPV Vaccine Cuts Rate Of Cervical Cancer By Almost 90%

The vaccine for human papillomavirus (HPV) decreases cervical cancer rates by nearly 90%, according to a study published by The Lancet on Wednesday.

Cervical cancers are the fourth most common cancer in women, killing more than 300,000 people a year, and are caused by viruses, BBC News reported. The study showed the HPV vaccine cut rates of cervical cancer in women by 87%.

Approximately 99% of cervical cancers are caused by HPV, the most common sexually transmitted virus in the U.S., CNN reported. While the virus is usually resolved on its own, certain types of the virus can put women at increased risk of cervical cancer.

Researchers for the Lacet study looked at cancer registry data in the U.K. between January 2006 and June 2019 among seven groups of women, comparing the vaccinated to the unvaccinated. The study estimated there were 450 fewer cases of cervical cancer and 17,200 fewer cases of pre-cancers than expected in those who received the vaccine.

“This study provides the first direct evidence of the impact of the UK HPV vaccination campaign on cervical cancer incidence, showing a large reduction in cervical cancer rates in vaccinated cohorts,” study co-author Dr. Kate Soldan from the U.K. Health Security Agency said, CNN reported.

“This represents an important step forwards in cervical cancer prevention,” she added. “We hope that these new results encourage uptake as the success of the vaccination program relies not only on the efficacy of the vaccine but also the proportion of the population vaccinated.”

Researchers also said the results of the study showed the need for smear tests, which women use to screen for cervical cancer every three to five years, could significantly decrease with vaccination, the BBC reported.

The Centers for Disease Control and Prevention began recommending girls 11-12 years old get the HPV vaccine in 2006, CNN reported. The American Academy of Pediatrics found in 2021 that vaccination rates among young adults were getting better, but less than half had received one dose or more.